Closure container for single dose disposable pharmaceutical delivery system

ABSTRACT

The disposable unit dose pharmaceutical delivery system may be used by trained medical personnel for intradermal or subcutaneous injections in applications currently being serviced by conventional pre-filled syringes. The delivery system may also be used by personnel with little or no medical training for mass immunizations in underdeveloped parts of the world, insulin injections, and/or emergency epinephrine injections. The delivery system includes an envelope with a tear-away section and a dispensing section. When the tear-away section has been removed, a needle is exposed and is ready for insertion in the patient. The dispensing portion is squeezed between the thumb and forefinger to inject the pharmaceutical into the patient. The exterior surface of the envelope may be used for advertising by a pharmaceutical producer, a supplier or otherwise.

CROSS REFERENCE

Applicant claims benefit of provisional patent application No.60/746,261 filed on May 3, 2006 entitled “SeraTouch”.

BACKGROUND OF THE INVENTION

This invention relates to closure containers for single dose disposablepharmaceutical delivery systems. The system has particular advantage forbattlefield applications, mass immunizations in underdeveloped areas ofthe world and other general medical applications currently beingserviced by pre-filled syringes.

During World War II Squibb, now Bristol-Myers Squibb, developed themorphine Syrette® disposable present invention. It consisted of a smalltube of morphine with an attached hypodermic needle. Medical personnelfirst had to break a seal with a small needle. The morphine wasadministered by piercing the patient's skin with the needle and thensqueezing the tube.

A number of prior art patents for a disposable single dose dispenserutilize a moveable needle to puncture the container holding thepharmaceutical including: U.S. Pat. Nos. 2,676,591; 2,687,727;2,693,183; 3,192,925 and 4,883,473. The present invention does notutilize a moveable needle to puncture the container holding thepharmaceutical.

U.S. Pat. No. 2,618,263 for a “Disposable Single-Use Syringe” ” is adisposable, single use, prefilled unit dose pharmaceutical deliverysystem; however, the structural design is different from the presentinvention. In the '263 patent, the ampoule is easily moved by a fingerso that the needle punctures the ampoule, whereupon with furtherpressure being exerted on the ampoule, the contents thereof is expressedthrough the needle for the intended function of the syringe. The needlein the present invention is straight and the needle in the '263 patentis not.

U.S. Pat. No. 3,736,933 is a “Burstable Seamed Hypodermic Applicator.”This prior art patent does not show a single dispensing apparatus with asingle cap. Rather, the '933 patent discloses a plurality of dispensingapplicators in a single elongate shield to receive and cap multipleneedles. In other words, this patent discloses a package with severaldispensing applicators that can be selectively withdrawn from the singleelongate shield/cap. The present invention uses a single shield/cap foreach dispensing apparatus.

U.S. Pat. No. 4,548,601 is a “Prepackaged, Injectable Pharmaceutical andHypodermic Needle Combination.” The combination is a disposable, singleuse, prefilled unit dose pharmaceutical delivery system; however, thestructural design is different from the present invention. In the '601patent, “the injectable medication is contained within a substantiallynon-resilient, highly flexible sack or inner container which isindirectly compressed, pneumatically, by means of a resilient,comparatively rigid outer container. Manual collapsing pressure orsqueezing of the outer container serves, in successive operations, tocompletely discharge the contents of the inner container through acannulae, thereby injecting its full dose.” The present invention doesnot use the pneumatic pump of this prior art patent; instead, thepresent invention relies on manual pressure of the thumb and forefingerto discharge the pharmaceutical from the bladder. This prior art patentdiscloses a rupture seal, but no fill port.

U.S. Pat. No. 4,955,871 is a “Single-Use Disposable Syringe” that isprefilled unit dose pharmaceutical delivery system; however, thestructural design is different from the present invention. The '871patent is designed to allow aspiration for intramuscular and intravenousinjections whereas the present invention is not designed for aspiration.The '871 patent is designed to create negative pressure in a reservoirmeans 46 formed from a pair of sheets 38 a and 38 b. The bladder of thepresent invention is not designed to create negative pressure. Thepresent invention uses a needle seal that is ruptured by pressure. The'871 patent uses the sharp end of the needle to penetrate the nozzlemembrane 22. The '871 patent discloses a fill port 58 for the reservoir46, but no rupture seal.

U.S. Pat. No. 5,019,048 is a “Unit Dose Syringe with Rotatable Needle.”This prior art patent discloses a disposable, single use, prefilled unitdose pharmaceutical delivery system; however, the structural design isdifferent from the present invention. FIGS. 7 and 8 show an embodimentwherein a needle 55 is connected to a plastic squeeze bag 56 by anunstructured flexible plastic fitting at 57 in the manner of a bagpipewhere the needle is analogous to the pipe of the bagpipe. FIG. 7 showsthe needle 55 in the protected position inside a pocket 59. Pocket 59includes a tear strip, not shown, which is removed to allow needle 55 toassume the position shown in FIG. 8. In use, a chuck 60 grips the needleas shown in FIG. 9. Once the needle is secured in the chuck, thecontents of the bag are easily administered. Unlike this prior artpatent, the present invention does not have a separate chuck foradministration of the pharmaceutical, nor does the present inventionhave a rotating needle.

U.S. Pat. No. 5,810,783 is a “Medication Injector” which is adisposable, single use, prefilled unit dose pharmaceutical deliverysystem; however, the structural design is different from the presentinvention. To avoid fluid escape during storage, from this prior artpatent, the needle 4 is enclosed in a flexible plastic tube 5, closed atits distal end 6 by heat-sealing, to keep air inside the needle 4,acting as a blockage to the fluid. The tube 5 is further enclosed in anair tight envelope 7 as best seen in FIGS. 1A and 2 of this prior artpatent. The present invention uses a single cap to shield the needle,unlike this two part shielding system in the '783 patent.

Owen Mumford Ltd. of Oxon in the United Kingdom advertises a“Snapdragon” single use disposable auto injector on the website,www.owenmumfore.com. The device is promoted as a single-use, disposable,safety injection device for use with a pre-filled glass syringe. Thepresent invention does not use a pre-filled glass syringe.

Many attempts have been made to produce a single dose disposablepharmaceutical delivery system to replace conventional prefilledsyringes; unfortunately none of these attempts have been economicallycompetitive. There remains a need for a reliable unit dose disposablepharmaceutical delivery system that is economical to produce.

SUMMARY OF THE INVENTION

The unit dose disposable pharmaceutical delivery system is formed as agenerally flat envelope about the size of a credit card having atear-away portion and a dispensing portion. The pharmaceutical is storedin a bladder and is dispensed through a needle that is stationary inrelationship to the bladder. In other words, the needle is not moved topuncture the bladder, prior to dispensing of the pharmaceutical. Thisdelivery system is used to make intradermal or subcutaneous injectionsand thus the exposed portion of the needle can be relatively short. Thissystem has particular advantage for battlefield applications, massimmunizations in underdeveloped areas of the world, and other generalmedical applications currently being serviced by pre-filled syringes.The delivery system may also be helpful to numerous individuals that donot have formal medical training, such as for insulin injections and/oremergency epinephrine injections.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a top plan view of the unit dose disposable pharmaceuticaldelivery system with the tear-away portion of the envelope joined to thedelivery portion;

FIG. 2 is a section view of the unit dose disposable pharmaceuticaldelivery system of FIG. 1 along the line 2-2;

FIG. 3 is a top plan view of the unit dose disposable pharmaceuticaldelivery system with the tear away portion removed from the deliveryportion of the envelope;

FIG. 4 is a section view of the unit dose disposable pharmaceuticaldelivery system of FIG. 3 along the line 4-4;

FIG. 5 is a top plan view of the exploded components of the unit dosedisposable pharmaceutical delivery system; and

FIG. 6 is a section view of the exploded components of the unit dosedisposable pharmaceutical delivery system of FIG. 6 along the line 7-7.

DETAILED DESCRIPTION

This is a description of FIGS. 1-6 of the unit dose disposablepharmaceutical delivery system generally identified by the numeral 10.The delivery system 10 forms an envelope 12 which includes the tear-awayportion 14 and the dispensing portion 16. A tear line 18 divides thetear-away portion 14 from the dispensing portion 16. To separate the twoportions, the user merely tears and slightly rotates the tear-awayportion from the dispensing portion.

The envelope 12 may be formed from an anterior sheet 20 and a posteriorsheet 22. Depending on the application, other sheets may also be used,such as second anterior sheet 21 and second posterior sheet 23. Othersheets, not shown may also be necessary. The bladder 24 may be formedseparately from the sheets 20 and 22 or it may be defined by the sheets20 and 22. FIGS. 1-6 show the bladder 24 formed separately from sheets20, 21, 22 and 23.

In the preferred embodiment, the bladder may be formed from a relativelystiff anterior wall 26, and posterior wall 28 joined by a relativelyflexible side wall 30. The bladder may be formed in different shapesdepending on a variety of factors including the amount of the unit dose,the type of pharmaceutical and the intended application. The bladder maybe formed from any suitable material, but polyethylene or polypropyleneis preferred. The bladder 24 defines a chamber 25 to hold thepharmaceutical 27.

A rigid needle hub 32 is secured to the dispensing portion 16 of theenvelope 12. A hollow needle 34 extends from the needle hub and is in afixed position relative to the bladder. Unlike many prior art patents,the needle of the present invention does not move to puncture thebladder, prior to injection of the pharmaceutical. The needle may have asharp point 36, a crown point 38, such as used by allergists or someother design. Any gauge needle may be used, but from about 22 gauge toabout 29 gauge is preferred. A needle cap 40 is secured to the tear-awayportion of the envelope and has a cavity 42 sized and arranged toreceive the exposed portion of the needle 44. The exposed portion of theneedle may be of any length including from about 0.25 inches to about1.0 inches. When injecting the pharmaceutical, the bladder 24 is influid communication with the needle 34. However, prior to the injection,the bladder may or may not be in fluid communication with the needle asdiscussed below.

The delivery system may be used for any size unit dose, but preferablyfrom about 0.5 cc to about 3.0 cc. The delivery system 10 may use theneedle cap to seal the pharmaceutical in the bladder or the deliverysystem may have one or more seals used in addition to or in lieu of theneedle cap. For example, a bladder seal 46 may be positioned between thebladder and the needle as better seen in FIGS. 5 and 6. When pressure isapplied to the bladder by the thumb and forefinger, the pressurizedpharmaceutical ruptures the bladder seal 46 and flows into the needle34. The delivery system 10 may use the needle cap to seal thepharmaceutical in the bladder, as previously mentioned or the deliverysystem may use the bladder seal 46 and/or a needle hub seal 48, asbetter seen in FIGS. 5 and 6. Again, the pressurized pharmaceuticalruptures the needle hub seal 48 and/or the bladder seal 46 allowing thepharmaceutical to flow into the needle 34. Other rupture seals, notshow, may also be used in this delivery system in conjunction with or inlieu of the bladder seal 46, the needle hub seal 48 and/or the needlecap 40.

A fill port 50 may be positioned in the bladder to facilitate filling ofthe bladder with the pharmaceutical. The fill port may be formed from asoft elastomeric compound which is easily pierced by a fill needleduring the manufacturing process. In the alternative, the bladder may befilled in other ways without the need for a fill port.

The exterior surface 51 of the envelope may be printed with varioustypes of indicia, including but not limited to, pharmaceutical indicia54 to identify the name of the pharmaceutical in the delivery system,unit dose indicia 56 to indicate the amount of the pharmaceutical in thedelivery system, needle gauge indicia 58 and needle length indicia 59.For advertising purposes, supplier indicia 60 to indicate the maker ofthe pharmaceutical, such as Pfizer, or the producer of the deliverysystem, such as Becton and Dickinson, commonly abbreviated to BD in theindustry.

1. A single dose disposable pharmaceutical delivery system comprising:an envelope having a tear-away portion and a dispensing portion; indiciaon an exterior of the envelope with a name of a supplier; the dispensingportion having a bladder to contain the pharmaceutical; the dispensingportion also having a needle secured to a needle hub, the needle beingin a stationary position relative to the bladder; and the tear-awayportion having an internal cap to protect an exposed portion of theneedle.
 2. The apparatus of claim 1 further including at least one sealto retain the pharmaceutical in the bladder.
 3. The apparatus of claim 1further including an elastomeric fill port to facilitate filling of thebladder with the pharmaceutical.
 4. The apparatus of claim 1 furtherincluding indicia on an exterior of the envelope with a unit dose and apharmaceutical name.
 5. A single dose disposable delivery systemcomprising: an envelope having a tear-away portion and a dispensingportion; indicia on an exterior of the envelope with a name of asupplier: the dispensing portion having a bladder to contain apharmaceutical; the dispensing portion also having a needle hub and aneedle fixedly attached to and extending from the needle hub; and thetear away portion having a cap to protect a sharp end of the needle. 6.The apparatus of claim 5 further including at least one seal to assistin retention of the pharmaceutical in the bladder.
 7. The apparatus ofclaim 5 further including an elastomeric fill port to facilitate fillingof the bladder with the pharmaceutical.
 8. The apparatus of claim 5further including indicia on an exterior of the envelope with a unitdose and a pharmaceutical name.
 9. A single dose disposablepharmaceutical delivery system comprising: an envelope having atear-away portion and a dispensing portion; the dispensing portionhaving a bladder and a seal to contain the pharmaceutical; thedispensing portion also having a needle hub and a needle extending fromand rigidly attached to the needle hub, the needle in fluidcommunication with the bladder; the tear-away portion having an internalcap to protect an exposed portion of the needle; and the bladder havinga fill port to facilitate filling of the bladder with thepharmaceutical.
 10. The apparatus of claim 9 further including indiciaon an exterior of the envelope with a unit dose and a pharmaceuticalname.
 11. The apparatus of claim 9 further including indicia on anexterior of the envelope with a name of a supplier.
 12. A single dosedisposable pharmaceutical delivery system comprising: an envelope havinga tear-away portion and a dispensing portion; the dispensing portionhaving a bladder to contain the pharmaceutical; the dispensing portionalso having a needle secured to a needle hub, the needle being in astationary position relative to the bladder; at least one seal attachedto the needle hub to assist in retaining the pharmaceutical in thebladder; the tear-away portion having an internal cap to protect anexposed portion of the needle; and the bladder having a fill port tofacilitate filling of the bladder with the pharmaceutical.
 13. Theapparatus of claim 12 further including indicia on an exterior of theenvelope with a unit dose and a pharmaceutical name.
 14. The apparatusof claim 12 further including indicia on an exterior of the envelopewith a name of a supplier.